Celldex Therapeutics reported that barzolvolimab met primary and key secondary endpoints in two Phase 3 chronic spontaneous urticaria trials involving 1,939 randomized patients. For investors, the stated next steps are continued treatment through 52 weeks and a planned Biologics License Application submission in 2027.

Key Highlights

  • The EMBARQ-CSU program randomized 1,939 adults across its two Phase 3 studies.
  • Complete response at Week 12 ranged from 42.1% to 45.7% across the two barzolvolimab dose groups and trials.
  • Celldex plans to continue treatment through 52 weeks and submit a Biologics License Application in 2027.

The studies evaluated adults with chronic spontaneous urticaria whose symptoms were inadequately controlled by H1-antihistamines. Across both trials, 1,939 patients were randomized to barzolvolimab or placebo. The two dosing groups were 150 mg Q4W and 300 mg Q8W.

Barzolvolimab Hits Week 12 Targets

In EMBARQ-CSU1, the least-squares mean change was -20.2 for the 150 mg Q4W group and -20.5 for the 300 mg Q8W group, compared with -10.7 for placebo. EMBARQ-CSU2 recorded a least-squares mean change of -20.2 for 150 mg Q4W and -19.7 for 300 mg Q8W, while placebo showed -11.4. The reported p-values for the active treatment comparisons were less than.00001. Complete response was defined as a UAS7 score of zero, representing the absence of itch and hives. At Week 12, the 150 mg Q4W group recorded complete response rates of 42.4% in EMBARQ-CSU1 and 45.7% in EMBARQ-CSU2. The corresponding rates for 300 mg Q8W were 42.1% and 44.0%. The placebo complete response rates at that point were 9.3% in EMBARQ-CSU1 and 12.6% in EMBARQ-CSU2. Celldex (NASDAQ: CLDX) said all key secondary endpoints were met in both studies at Week 12.

Responses Deepen Through Week 24

The complete response rates increased at Week 24. Patients receiving 150 mg Q4W reached 49.0% in EMBARQ-CSU1 and 54.0% in EMBARQ-CSU2, while the 300 mg Q8W group reached 45.1% and 48.4%, respectively. Placebo rates at Week 24 were 15.4% in EMBARQ-CSU1 and 17.6% in EMBARQ-CSU2. The company also reported results for participants whose chronic spontaneous urticaria was refractory to omalizumab. At Week 12, complete response in that subgroup reached 55.3% with 150 mg Q4W in EMBARQ-CSU1 and 41.7% in EMBARQ-CSU2. The 300 mg Q8W group recorded 44.3% and 46.4%, respectively. Among patients with baseline angioedema activity, the proportion reaching an AAS7 score of zero at Week 12 was 62.7% and 74.3% with 150 mg Q4W across EMBARQ-CSU1 and EMBARQ-CSU2. The 300 mg Q8W group recorded 66.3% and 66.2%, while placebo recorded 33.8% and 33.7%.

Treatment Continues To 52 Weeks

Patients received 150 mg every four weeks after a 300 mg loading dose, 300 mg every eight weeks after a 450 mg loading dose, or placebo. The active-treatment groups continue for 52 weeks. Celldex plans to submit a Biologics License Application in 2027. The company also said it intends to present the EMBARQ-CSU results at an upcoming medical meeting.